Antioxidant Therapy for Smith-Lemli-Opitz Syndrone

PROCUREMENT OVERVIEW

The Department of Health and Human Services (HHS) is seeking proposals for an Antioxidant Therapy specifically targeting Smith-Lemli-Opitz Syndrome (SLOS). The project aims to develop and implement a therapeutic solution that addresses the biochemical deficiencies associated with SLOS, which is a genetic disorder affecting cholesterol synthesis. The core need is to enhance patient outcomes through effective antioxidant treatment, thereby improving the quality of life for individuals affected by this syndrome.

ISSUING ORGANIZATION

The issuing organization is the Department of Health and Human Services (HHS), located in Washington, DC, United States. The primary contact for this opportunity is Niamh Cawley, who can be reached at [email protected].

KEY DATES

• Posted Date: August 3, 2026
• Proposal Due Date: August 18, 2026
• Anticipated Award Date: Not specified
• Performance Period: Not specified

CONTRACT DETAILS

The contract type is not explicitly stated in the opportunity metadata. There is no estimated contract value or budget range mentioned, nor are there any option years indicated.

MANDATORY REQUIREMENTS

Bidders must meet the following mandatory requirements to be considered eligible:

• Certifications and Registrations: Registration in SAM.gov is required.
• Security Clearances: No specific security clearances are mentioned.
• Set-aside Restrictions: There are no set-aside restrictions indicated.
• Geographic Restrictions: No geographic restrictions or place-of-performance requirements are specified.
• Experience Requirements: Minimum years of experience or past performance requirements are not detailed.
• Bonding or Insurance Requirements: Not mentioned.

TECHNICAL CAPABILITIES

Bidders should possess specific technical skills and domain expertise in antioxidant therapies and genetic disorders, particularly in relation to cholesterol synthesis and metabolic disorders. Familiarity with clinical trial methodologies and regulatory compliance for therapeutic development is likely essential.

DELIVERABLES AND PERFORMANCE STANDARDS

Key deliverables and performance standards are not explicitly outlined in the provided information. Bidders should anticipate the need for regular progress reports and adherence to clinical trial milestones, though specific metrics or service-level agreements are not detailed.

EVALUATION CRITERIA

The evaluation criteria for proposals have not been specified in the opportunity metadata. Bidders should prepare to demonstrate their technical approach, past performance, and pricing strategy, as these are typically critical factors in government procurement evaluations.

PREFERRED QUALIFICATIONS

While not mandatory, preferred qualifications that could provide a competitive advantage may include:

• Advanced certifications in clinical research or therapeutic development.
• Proven experience in developing treatments for genetic disorders.
• Established partnerships with academic or research institutions in relevant fields.

This summary provides a comprehensive overview of the opportunity for bidders to assess their fit and prepare their proposals accordingly.